Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activity. Sulindac sulfide amide (1) possessing greatly reduced COX-related inhibition relative to sulindac displayed in vivo antitumor activity that was comparable to sulindac in a human colon tumor xenograft model. Inspired by these observations, a panel of diverse sulindac amide derivatives have been synthesized and their activity probed against three cancer cell lines (prostate, colon and breast). A neutral analog, compound 79 was identified with comparable potency relative to lead 1 and activity against a panel of lymphoblastic leukemia cell lines. Several new series also show good activity relative to the parent (1), including five analogs that also possess nanomolar inhibitory potencies against acute lymphoblastic leukemia cells. Several new analogs identified may serve as anticancer lead candidates for further development.

舒林酸是一种非甾体抗炎药（NSAID），已显示出显着的抗癌活性。相对于舒林酸，舒林酸硫化物酰胺（1）具有大大降低的COX相关抑制作用，在人结肠肿瘤异种移植模型中具有与舒林酸相当的体内抗肿瘤活性。受这些观察结果的启发，已经合成了一组不同的舒林酸酰胺衍生物，并针对三种癌细胞系（前列腺癌，结肠癌和乳腺癌）探测了它们的活性。鉴定出一种中性类似物化合物79具有相对于铅1相当的效力，并且对一组淋巴细胞性白血病细胞系具有活性。相对于父系，几个新系列也表现出良好的活动性（1），包括五个类似的类似物，它们也具有针对急性淋巴细胞白血病细胞的纳摩尔抑制力。鉴定出的几种新的类似物可作为抗癌药物的潜在候选者，以进行进一步的开发。